Development and Technology Out-Licensing of API Purification and Manufacturing Processes by the SI Center
First written in FY2018. 4 of 5 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「We also examine new synthesis and purification processes for active pharmaceutical ingredients, propose quality improvements and provide technologies for new manufacturing processes to active pharmaceutical ingredient manufacturers, and provide technical support to ensure a stable supply of high-quality, low-cost active pharmaceutical ingredients.」
The company continues to support suppliers by examining synthesis and purification processes for active pharmaceutical ingredients, proposing quality improvements and providing technology for new manufacturing processes. - FY2025RestatedAnnual report
「We also examine new synthesis and purification processes for active pharmaceutical ingredients, propose quality improvements and provide technologies for new manufacturing processes to active pharmaceutical ingredient manufacturers, and provide technical support to ensure a stable supply of high-quality, low-cost active pharmaceutical ingredients.」
The company continues to examine synthesis and purification processes for active pharmaceutical ingredients and propose quality improvements and provide technology to active pharmaceutical ingredient manufacturers. - FY2021RestatedAnnual report
「At the SI Center owned by コーア商事株式会社, we focus on developing new purification processes that yield high-quality active pharmaceutical ingredients and manufacturing processes that enable low-cost synthesis, and deepen cooperation by transferring these technologies to overseas suppliers,」
The company has reaffirmed the development of purification and manufacturing processes at the SI Center and the transfer of technology to overseas suppliers. - FY2019RestatedAnnual report
「At the SI Center owned by コーア商事株式会社, we focus on developing new purification processes that yield high-quality active pharmaceutical ingredients and manufacturing processes that enable low-cost synthesis, and transfer these technologies to overseas suppliers,」
The company has reaffirmed the development of purification and manufacturing processes at the SI Center and the transfer of technology to overseas suppliers. - FY2018First statedAnnual report
「At the SI Center owned by コーア商事株式会社, we focus on developing new purification processes that yield high-quality active pharmaceutical ingredients and manufacturing processes that enable low-cost synthesis, and transfer these technologies to overseas suppliers.」
A measure to support the supply of high-quality, low-cost active pharmaceutical ingredients through technology.